3 Citations (Scopus)

Abstract

Calcium phosphate ceramic has been known for its properties of bioactivity and osteoconductivity and has been widely used in orthopedic, plastic and craniofacial surgeries. The biocompatibility, unlimited availability, lower morbidity for the patient and cost-effectiveness of calcium phosphate ceramics represent important advantages over other biological bone graft, such as autografts and allografts. A new synthetic biphasic calcium phosphate (BCP), Bicera™ (60% HA and 40% β-TCP), is manufactured by Wiltrom Co., Ltd., as a new bone graft substitute. It shows good biocompatibility without cytotoxicity in in vitro test. To evaluate the possible application for clinical use, we used New Zealand white rabbit femur defect model to compare the osteoconductivity of this new bone substitute to another commercially available bone substitute (Triosite®) which was used as the control material. According to the macroscopic observation, both bone substitutes show good biocompatibility and no abnormal inflammation either infection was seen at the implantation sites. X-rays image of implant sites at one month, three months and six months showed all implanted materials were well incorporated with host bone. All of them were not fully absorbed and replaced after six months implantation. In the histological and hitomorphometric data, new bone grew into the surface of the peripheral pores in both bone substitutes and increased over time. Moreover, the degree of bone regeneration appeared to be relatively greater in the specimens with Bicera™ when compared with Triosite ®. We concluded that this new synthetic BCP (Bicera™) showed similar biocompatibility and osteoconductive characteristic comparing with commercial product Triosite® in rabbit femur defects model.

Original languageEnglish
Pages (from-to)537-548
Number of pages12
JournalBiomedical Engineering - Applications, Basis and Communications
Volume24
Issue number6
DOIs
Publication statusPublished - Dec 2012

Fingerprint

Bone Substitutes
Calcium phosphate
Femur
Bone
Biocompatibility
Rabbits
Defects
Ceramics
Bone and Bones
Grafts
Transplants
Bone Regeneration
Autografts
Orthopedics
Plastic Surgery
Cytotoxicity
Cost effectiveness
Bioactivity
Surgery
Cost-Benefit Analysis

Keywords

  • Biphasic calcium phosphate
  • Bone substitute
  • Fracture healing

ASJC Scopus subject areas

  • Biophysics
  • Biomedical Engineering
  • Bioengineering

Cite this

@article{7bbfe90e8626468ba69a501286d976f5,
title = "In vivo evaluation of a new biphasic calcium phosphate bone substitute in rabbit femur defects model",
abstract = "Calcium phosphate ceramic has been known for its properties of bioactivity and osteoconductivity and has been widely used in orthopedic, plastic and craniofacial surgeries. The biocompatibility, unlimited availability, lower morbidity for the patient and cost-effectiveness of calcium phosphate ceramics represent important advantages over other biological bone graft, such as autografts and allografts. A new synthetic biphasic calcium phosphate (BCP), Bicera™ (60{\%} HA and 40{\%} β-TCP), is manufactured by Wiltrom Co., Ltd., as a new bone graft substitute. It shows good biocompatibility without cytotoxicity in in vitro test. To evaluate the possible application for clinical use, we used New Zealand white rabbit femur defect model to compare the osteoconductivity of this new bone substitute to another commercially available bone substitute (Triosite{\circledR}) which was used as the control material. According to the macroscopic observation, both bone substitutes show good biocompatibility and no abnormal inflammation either infection was seen at the implantation sites. X-rays image of implant sites at one month, three months and six months showed all implanted materials were well incorporated with host bone. All of them were not fully absorbed and replaced after six months implantation. In the histological and hitomorphometric data, new bone grew into the surface of the peripheral pores in both bone substitutes and increased over time. Moreover, the degree of bone regeneration appeared to be relatively greater in the specimens with Bicera™ when compared with Triosite {\circledR}. We concluded that this new synthetic BCP (Bicera™) showed similar biocompatibility and osteoconductive characteristic comparing with commercial product Triosite{\circledR} in rabbit femur defects model.",
keywords = "Biphasic calcium phosphate, Bone substitute, Fracture healing",
author = "Chen, {Chia Hsien} and Chiang, {Chang Jung} and Gary Rau and Huang, {Mao Suan} and Chan, {Kam Kong} and Liao, {Chun Jen} and Kuo, {Yi Jie}",
year = "2012",
month = "12",
doi = "10.1142/S1016237212500494",
language = "English",
volume = "24",
pages = "537--548",
journal = "Journal of Chinese Corrosion Engineering",
issn = "1016-2372",
publisher = "World Scientific Publishing Co. Pte Ltd",
number = "6",

}

TY - JOUR

T1 - In vivo evaluation of a new biphasic calcium phosphate bone substitute in rabbit femur defects model

AU - Chen, Chia Hsien

AU - Chiang, Chang Jung

AU - Rau, Gary

AU - Huang, Mao Suan

AU - Chan, Kam Kong

AU - Liao, Chun Jen

AU - Kuo, Yi Jie

PY - 2012/12

Y1 - 2012/12

N2 - Calcium phosphate ceramic has been known for its properties of bioactivity and osteoconductivity and has been widely used in orthopedic, plastic and craniofacial surgeries. The biocompatibility, unlimited availability, lower morbidity for the patient and cost-effectiveness of calcium phosphate ceramics represent important advantages over other biological bone graft, such as autografts and allografts. A new synthetic biphasic calcium phosphate (BCP), Bicera™ (60% HA and 40% β-TCP), is manufactured by Wiltrom Co., Ltd., as a new bone graft substitute. It shows good biocompatibility without cytotoxicity in in vitro test. To evaluate the possible application for clinical use, we used New Zealand white rabbit femur defect model to compare the osteoconductivity of this new bone substitute to another commercially available bone substitute (Triosite®) which was used as the control material. According to the macroscopic observation, both bone substitutes show good biocompatibility and no abnormal inflammation either infection was seen at the implantation sites. X-rays image of implant sites at one month, three months and six months showed all implanted materials were well incorporated with host bone. All of them were not fully absorbed and replaced after six months implantation. In the histological and hitomorphometric data, new bone grew into the surface of the peripheral pores in both bone substitutes and increased over time. Moreover, the degree of bone regeneration appeared to be relatively greater in the specimens with Bicera™ when compared with Triosite ®. We concluded that this new synthetic BCP (Bicera™) showed similar biocompatibility and osteoconductive characteristic comparing with commercial product Triosite® in rabbit femur defects model.

AB - Calcium phosphate ceramic has been known for its properties of bioactivity and osteoconductivity and has been widely used in orthopedic, plastic and craniofacial surgeries. The biocompatibility, unlimited availability, lower morbidity for the patient and cost-effectiveness of calcium phosphate ceramics represent important advantages over other biological bone graft, such as autografts and allografts. A new synthetic biphasic calcium phosphate (BCP), Bicera™ (60% HA and 40% β-TCP), is manufactured by Wiltrom Co., Ltd., as a new bone graft substitute. It shows good biocompatibility without cytotoxicity in in vitro test. To evaluate the possible application for clinical use, we used New Zealand white rabbit femur defect model to compare the osteoconductivity of this new bone substitute to another commercially available bone substitute (Triosite®) which was used as the control material. According to the macroscopic observation, both bone substitutes show good biocompatibility and no abnormal inflammation either infection was seen at the implantation sites. X-rays image of implant sites at one month, three months and six months showed all implanted materials were well incorporated with host bone. All of them were not fully absorbed and replaced after six months implantation. In the histological and hitomorphometric data, new bone grew into the surface of the peripheral pores in both bone substitutes and increased over time. Moreover, the degree of bone regeneration appeared to be relatively greater in the specimens with Bicera™ when compared with Triosite ®. We concluded that this new synthetic BCP (Bicera™) showed similar biocompatibility and osteoconductive characteristic comparing with commercial product Triosite® in rabbit femur defects model.

KW - Biphasic calcium phosphate

KW - Bone substitute

KW - Fracture healing

UR - http://www.scopus.com/inward/record.url?scp=84871204624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871204624&partnerID=8YFLogxK

U2 - 10.1142/S1016237212500494

DO - 10.1142/S1016237212500494

M3 - Article

AN - SCOPUS:84871204624

VL - 24

SP - 537

EP - 548

JO - Journal of Chinese Corrosion Engineering

JF - Journal of Chinese Corrosion Engineering

SN - 1016-2372

IS - 6

ER -